Prion protein in Alzheimer's diseases

Future Neurology

Volumn 2, Issue 6, 2007, Pages 587-590

  Watt, Nicole T ^a   Hooper, Nigel M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; PRION PROTEIN; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; EDITORIAL; ENZYME INHIBITION; HUMAN; NERVE CELL LESION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION;

EID: 36148970409     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.6.587     Document Type: Editorial

References (18)

1. Vardy ER, Hussain I, Hooper NM: Emerging therapeutics for Alzhelmer's disease. Expert Rev. Neurother. 6(5). 695-704 (2006).
2. Mattson MP: Pathways towards and away from Alzheimer's disease. Nature 430(7000), 631-639 (2004).
3. Watts JC, Balachandran A, Westaway D: The expanding universe of prion diseases. PLoS Pathog. 2(3), e26 (2006).
4. C): Its physiological function and role in disease. Biochim. Biophys. Acta 1772(6), 629-644 (2007).
5. Parkin ET, Watt NT, Hussain I et al.: Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc. Natl Acad. Sci. USA 104(26), 11062-11067 (2007).
6. Kitamoto T, Iizuka R, Tateishi J: An amber mutation of prion protein in Gerstmann-Straussler syndrome with mutant PrP plaques. Biochem. Biophys. Res. Commun. 192(2), 525-531 (1993).
7. Finckh U, Muller-Thomsen T, Mann U et al.: High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am. J. Hum. Genet. 66(1). 110-117 (2000).
8. Halliwell B: Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97(6), 1634-1658 (2006).
9. Lee HG, Perry G, Moreira PI et al.: Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol. Med. 11(4), 164-169 (2005).
10. Butterfield DA, Reed T, Newman SF, Sultana R: Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 43.(5), 658-677 (2007).
11. Zhu X, Su B, Wang X, Smith MA, Perry G: Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 64(17), 2202-2210 (2007).
12. Nunomura A, Castellani RJ, Zhu X et al.: Involvement of oxidative stress in Alzheimer disease. J. Neuropathol. Exp. Neurol. 65(7), 631-641 (2006).
13. Petersen RB, Siedlak SL, Lee HG et al.: Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol. (Berl) 110(3), 232-238 (2005).
14. Castellani RJ, Lee HG, Perry G, Smith MA: Antioxidant protection and neurodegenerative disease: the role of amyloid-β and tau. Am. J. Alzheimers Dis. Other Demen. 21(2), 126-130 (2006).
15. Vassallo N, Herms J: Cellular prion protein function in copper homeostasis and redox signalling at the synapse. J. Neurochem. 86(3), 538-544 (2003).
16. Watt NT, Taylor DR, Gillott A et al.: Reactive oxygen specles-mediated β-cleavage of the prion protein in the cellular response to oxidative stress. J. Biol. Chem. 280(43), 35914-35921 (2005).
17. Williams WM, Stadtman ER, Moskovitz J: Ageing and exposure to oxidative stress in vivo differentially affect cellular levels of PrP in mouse cerebral microvessels and brain parenchyma. Neuropathol. Appl. Neurobiol. 30(2), 161-168 (2004).
18. Coitinho AS, Roesler R, Martins VR, Brentani RR, Izquierdo I: Celullar prion protein ablation impairs-behavior as a function of age. Neuroreport 14(10), 1375-1379 (2003).